explore -WSS

explore

author：focus 2025-08-26 23:48:08 - browse：68999

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss than the obesity therapy Wegovy, the company reported Thursday, citing early data.

In a Phase 1 trial, participants experienced an average of 13.1% weight loss after 12 weeks of taking the experimental oral medicine amycretin, according to data presented at an investor meeting. In comparison, in an earlier Phase 3 trial of the injectable drug Wegovy, people taking Wegovy lost about 6% of their body weight over the same time period.

Novo Nordisk has been on a mission to capitalize on its success with Wegovy, which brought in $4.5 billion in sales last year. (The drug is also sold as a diabetes treatment under the name Ozempic. That version of the drug brought in another $14 billion in sales).

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Francis Collins on trust in science and how Covid communications failed

WSS

Test for long Covid? Researchers find new clue in blood samples

Sweeping indictment could be Trump's biggest legal challenge yet: ANALYSIS

Megan Rapinoe shares emotional post following US Women's World Cup exit

NIH director takes cautious approach to Biden drug pricing priority

Novo Nordisk touts Wegovy study, but still struggling with supply

Novo Nordisk touts Wegovy study, but still struggling with supply

leisure time

explore

Wikipedia

Supreme Court strikes down use of affirmative action

FDA clears AI tool for detecting skin cancer

State Dept. review finds Biden bears some blame for Afghanistan failures

The tragedy of Johnson & Johnson’s Covid vaccine

Medicare proposal to cover medical devices draws a mixed reaction

BMS, looking to build heart drug business, turns to AI for diagnosis

Apple is now the first public company to be valued at $3 trillion

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

In Memoriam: Notable people who died in 2023

Biotech venture capitalists face new demands from investors

explore

Biden administration begins canceling student loan debt for 804,000 borrowers

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

New brain studies show LSD's effects on the brain in full color

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Test for long Covid? Researchers find new clue in blood samples

entertainment

knowledge

knowledge

focus